P/E ratio for Vanda Pharmaceuticals (VNDA)
P/E ratio as of April 2024 (TTM): 17.1
According to Vanda Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 17.1111. At the end of 2022 the company had a P/E ratio of 61.6.
P/E ratio history for Vanda Pharmaceuticals from 2006 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 61.6 | 135.5% |
| 2021 | 26.2 | -14.43% |
| 2020 | 30.6 | 304.09% |
| 2019 | 7.56 | -85.53% |
| 2018 | 52.3 | -216.9% |
| 2017 | -44.7 | 17.72% |
| 2016 | -38.0 | 283.43% |
| 2015 | -9.90 | -126.28% |
| 2014 | 37.7 | -303.45% |
| 2013 | -18.5 | 390.59% |
| 2012 | -3.78 | -71.45% |
| 2011 | -13.2 | -136.34% |
| 2010 | 36.4 | -526.91% |
| 2009 | -8.52 | 3189.77% |
| 2008 | -0.2591 | -89.42% |
| 2007 | -2.45 | 3749.1% |
| 2006 | -0.0636 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.4 | -39.37% | 🇺🇸 USA |
 Novartis NVS | 26.1 | 52.26% | 🇨🇭 Switzerland |
 Pfizer PFE | 13.7 | -20.22% | 🇺🇸 USA |
 Eli Lilly LLY | 135 | 688.53% | 🇺🇸 USA |
 Merck MRK | 72.0 | 320.87% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 11.3 | -33.93% | 🇺🇸 USA |
 Titan Pharmaceuticals
TTNP | -11.9 | -169.41% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.